BioSpace News Archive

Operation Warp Speed succeeded on the development component but is failing in the early stages of distribution. Here’s everything you need to know about it.

Overnight, U.K. health authorities authorized the COVID-19 vaccine developed by AstraZeneca and Oxford University for emergency use.

Fabry disease is a rare, X-linked inherited disease that results from abnormal deposits of a fatty substance in blood vessels.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

Keeping in mind that COVID-19 has dominated the news cycle, here are the top 10 stories of 2020 in no particular order.

Sinopharm, a Chinese biopharmaceutical company controlled by the state, announced that its COVID-19 vaccine candidate had an efficacy rate of 79% based on interim analysis of Phase III trials.

A great deal remains unknown about the SARS-CoV-2 virus, its mutations, transmissibility and long-term effects. Here’s what we do know.

Pure Extracts Technologies Corp . (CSE: PULL) (XFRA: A2QJAJ) (“Pure Extracts” or the “Company”), a plant-based extraction company, is pleased to announce that it is commencing a study on the formulation and manufacturing of psilocybin based active treatments for oral tablets, capsules and a nasal gel that will be used as an investigational product. The study with be conducted at the Toronto Institute of Pharmaceutical Technology (

NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG announced the conclusion of enrollment in the phase 2b/3 trial of ZYESAMI™ for the treatment of Respiratory Failure in patients with Critical COVID-19.

Orexo AB, announces that the US Patent and Trademark Office has issued an additional patent for ZUBSOLV®, Orexo’s sublingual buprenorphine and naloxone tablet for the treatment of opioid use disorder.